EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced the granting of non-statutory stock options to fourteen new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options cover 362,500 shares of EyePoint common stock, with an exercise price of $14.63 per share, vesting over four years. The company is focused on developing and commercializing therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU, currently in Phase 3 trials.
APR 14·TipRanks→
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
EyePoint Pharmaceuticals provided an update on its DURAVYU Phase 3 trials for wet AMD and DME, confirming full enrollment for wet AMD trials with data expected mid-2026, and DME trial enrollment completion by Q3 2026. The company also reported a substantial cash runway into late 2027 and is advancing manufacturing scale-up for DURAVYU, positioning it for the large retinal anti-VEGF market. EyePoint (EYPT) currently holds a "Neutral" rating from Spark's AI Analyst, despite positive pipeline developments, due to financial performance concerns.
MAR 19·Traders Union▲
Eyepoint Pharmaceuticals pursues new therapies as anti-VEGF treatments fall short for DME patients
Eyepoint Pharmaceuticals is advancing its Phase 3 program for diabetic macular edema (DME) to address the limitations of existing anti-VEGF therapies. The company aims to develop more durable treatments that also tackle inflammation, filling a significant gap in current solutions for patients. These efforts are part of Eyepoint’s broader strategy to enhance its market position and product launches, supported by recent leadership appointments.
